HOLX Stock Overview
Engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
International Expansion And New Products Will Shape Future Of Women's Health
My Notes
Capture your thoughts, links and company narrative
Hologic, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$63.24 |
| 52 Week High | US$84.67 |
| 52 Week Low | US$62.94 |
| Beta | 0.98 |
| 1 Month Change | -9.31% |
| 3 Month Change | -19.74% |
| 1 Year Change | -14.30% |
| 3 Year Change | -9.72% |
| 5 Year Change | 20.25% |
| Change since IPO | 2,545.33% |
Recent News & Updates
Hologic, Inc. (NASDAQ:HOLX) Just Reported, And Analysts Assigned A US$80.53 Price Target
Feb 07
Is Hologic (NASDAQ:HOLX) A Risky Investment?
Jan 31Hologic: Reasonably, But Not Compellingly Valued
Jan 17Recent updates
Hologic, Inc. (NASDAQ:HOLX) Just Reported, And Analysts Assigned A US$80.53 Price Target
Feb 07Is Hologic (NASDAQ:HOLX) A Risky Investment?
Jan 31Hologic: Reasonably, But Not Compellingly Valued
Jan 17Here's What To Make Of Hologic's (NASDAQ:HOLX) Decelerating Rates Of Return
Jan 13Earnings Not Telling The Story For Hologic, Inc. (NASDAQ:HOLX)
Dec 22Hologic, Inc.'s (NASDAQ:HOLX) Intrinsic Value Is Potentially 60% Above Its Share Price
Dec 04When Should You Buy Hologic, Inc. (NASDAQ:HOLX)?
Nov 02Hologic: Continued Room Amidst Bolt-On M&A Efforts
Oct 28Hologic (NASDAQ:HOLX) Seems To Use Debt Rather Sparingly
Oct 17Hologic (NASDAQ:HOLX) Has More To Do To Multiply In Value Going Forward
Sep 16Hologic, Inc. (NASDAQ:HOLX) Not Flying Under The Radar
Sep 01Hologic Has A Lot Of Fine Qualities, But A Discount Valuation Isn't Among Them
Aug 27Is There Now An Opportunity In Hologic, Inc. (NASDAQ:HOLX)?
Jul 21These 4 Measures Indicate That Hologic (NASDAQ:HOLX) Is Using Debt Reasonably Well
Jun 20Returns At Hologic (NASDAQ:HOLX) Appear To Be Weighed Down
May 22Hologic: Women's Health Play Looks Healthier Itself
May 13Getting In Cheap On Hologic, Inc. (NASDAQ:HOLX) Might Be Difficult
Apr 19Calculating The Intrinsic Value Of Hologic, Inc. (NASDAQ:HOLX)
Apr 05Hologic (NASDAQ:HOLX) Has A Pretty Healthy Balance Sheet
Mar 20Why Hologic, Inc. (NASDAQ:HOLX) Could Be Worth Watching
Feb 22Hologic: Prospects For Growth As Headwinds Disappear
Feb 11Shareholder Returns
| HOLX | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -2.1% | 0.7% | 1.5% |
| 1Y | -14.3% | 13.0% | 22.4% |
Return vs Industry: HOLX underperformed the US Medical Equipment industry which returned 12.9% over the past year.
Return vs Market: HOLX underperformed the US Market which returned 22.2% over the past year.
Price Volatility
| HOLX volatility | |
|---|---|
| HOLX Average Weekly Movement | 3.7% |
| Medical Equipment Industry Average Movement | 7.9% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 18.0% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: HOLX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: HOLX's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1985 | 7,063 | Steve MacMillan | www.hologic.com |
Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.
Hologic, Inc. Fundamentals Summary
| HOLX fundamental statistics | |
|---|---|
| Market cap | US$14.19b |
| Earnings (TTM) | US$744.00m |
| Revenue (TTM) | US$4.04b |
19.1x
P/E Ratio3.5x
P/S RatioIs HOLX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HOLX income statement (TTM) | |
|---|---|
| Revenue | US$4.04b |
| Cost of Revenue | US$1.58b |
| Gross Profit | US$2.46b |
| Other Expenses | US$1.72b |
| Earnings | US$744.00m |
Last Reported Earnings
Dec 28, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.32 |
| Gross Margin | 60.93% |
| Net Profit Margin | 18.42% |
| Debt/Equity Ratio | 52.9% |
How did HOLX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/16 02:25 |
| End of Day Share Price | 2025/02/14 00:00 |
| Earnings | 2024/12/28 |
| Annual Earnings | 2024/09/28 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hologic, Inc. is covered by 51 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Ishan Majumdar | Baptista Research |
| Charles Butler | Barclays |